Stepan Company (SCL)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$63.42+1.67%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
Intact: The reason to own it still holds.
Stepan grew revenue from $554M to $604M in Q1 2026. The company beat EPS estimates by 15%. Management aims to grow adjusted EBITDA this year. Cost cuts may improve profit margins.
Stepan is loss-making and faces profit margin pressure. Earnings estimates have been cut recently. The company is behind on its EBITDA growth goal.
The price is about 13% above our fair value near $50. Analysts expect about 9% revenue growth, which matches our view.
Breaks if: Adjusted EBITDA does not grow in FY26
Continue delivering growth in Adjusted EBITDA for the full year 2026 despite market uncertainties and tariff challenges.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on operational efficiency and strategic growth. The current thesis is cautious, given the company's recent performance and ongoing management priorities.
The market appears to have priced in a high valuation, reflecting expectations that may not be fully justified. There is a significant expectations gap, suggesting that investors anticipate stronger performance than what has been demonstrated recently.
Management is on track to deliver growth in adjusted EBITDA and execute cost-saving initiatives. However, the company remains loss-making, and its recent financial performance has been neutral, indicating potential volatility ahead.
The thesis hinges on management's ability to maintain guidance and deliver on operational priorities. Additionally, external factors like inflation trends and performance of sector peers will play a crucial role in shaping the outlook.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Margin recovery is gaining pace, which reinforces expectations for full year Adjusted EBITDA growth. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Consolidated adjusted EBITDA grew from $108.9 million in first half 2025 to $124.1 million in first half 2026 (+14%). Q2 2026 adjusted EBITDA was $74.4 million, up 45% year-over-year. Management's trajectory is delivering growth as committed.
“We believe we will deliver full year Adjusted EBITDA growth, positive free cash flow and continue to de-leverage the balance sheet in 2026.”
“We believe we are positioned to deliver full year Adjusted EBITDA growth and positive free cash flow in 2026, despite ongoing market uncertainties.”
“We believe we are positioned to deliver full year Adjusted EBITDA growth and positive free cash flow in 2026, despite ongoing market and tariff uncertainties.”
Breaks if: Operating income does not improve over next year
Breaks if: YoY revenue growth falls below 9% next year
Management continues to emphasize revenue growth across key strategic businesses.
Over the next 1 to 3 years, SCL's performance will depend on effective execution of management strategies and external market conditions. Not investment advice.